Equities Analysts Offer Predictions for EW Q2 Earnings

Edwards Lifesciences Co. (NYSE:EW) – Equities research analysts at Zacks Research raised their Q2 2025 earnings per share estimates for shares of Edwards Lifesciences in a research report issued on Tuesday, May 13th. Zacks Research analyst R. Department now anticipates that the medical research company will earn $0.61 per share for the quarter, up from their previous estimate of $0.60. The consensus estimate for Edwards Lifesciences’ current full-year earnings is $2.45 per share. Zacks Research also issued estimates for Edwards Lifesciences’ FY2025 earnings at $2.42 EPS, Q2 2026 earnings at $0.69 EPS and Q4 2026 earnings at $0.72 EPS.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $0.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.60 by $0.04. The business had revenue of $1.41 billion during the quarter, compared to analysts’ expectations of $1.40 billion. Edwards Lifesciences had a return on equity of 19.40% and a net margin of 72.93%. The business’s quarterly revenue was up 6.2% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.66 EPS.

EW has been the subject of a number of other reports. Wolfe Research cut Edwards Lifesciences from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 12th. Morgan Stanley upped their target price on Edwards Lifesciences from $70.00 to $75.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 12th. Stifel Nicolaus raised Edwards Lifesciences from a “hold” rating to a “buy” rating and upped their target price for the company from $75.00 to $90.00 in a research report on Thursday, January 30th. Evercore ISI decreased their target price on Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a research report on Wednesday, February 12th. Finally, Truist Financial decreased their target price on Edwards Lifesciences from $78.00 to $75.00 and set a “hold” rating for the company in a research report on Friday, April 11th. One investment analyst has rated the stock with a sell rating, thirteen have issued a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $79.60.

Edwards Lifesciences Trading Up 1.3%

NYSE:EW opened at $77.92 on Friday. The stock has a 50-day simple moving average of $72.08 and a 200-day simple moving average of $71.73. The stock has a market cap of $45.71 billion, a P/E ratio of 11.18, a P/E/G ratio of 4.82 and a beta of 1.12. Edwards Lifesciences has a 1 year low of $58.93 and a 1 year high of $95.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Hedge Funds Weigh In On Edwards Lifesciences

Several hedge funds have recently bought and sold shares of the company. Woodline Partners LP increased its stake in Edwards Lifesciences by 7,805.0% in the 1st quarter. Woodline Partners LP now owns 825,358 shares of the medical research company’s stock valued at $59,822,000 after purchasing an additional 814,917 shares in the last quarter. MBB Public Markets I LLC purchased a new position in Edwards Lifesciences in the 1st quarter valued at approximately $313,000. Vancity Investment Management Ltd purchased a new position in Edwards Lifesciences in the 1st quarter valued at approximately $9,367,000. Caxton Associates LLP purchased a new position in Edwards Lifesciences during the first quarter worth $370,000. Finally, Sciencast Management LP purchased a new position in Edwards Lifesciences during the first quarter worth $208,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In related news, CFO Scott B. Ullem sold 11,250 shares of the firm’s stock in a transaction that occurred on Friday, February 28th. The stock was sold at an average price of $70.78, for a total value of $796,275.00. Following the completion of the transaction, the chief financial officer now directly owns 30,387 shares of the company’s stock, valued at $2,150,791.86. This trade represents a 27.02% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Donald E. Bobo, Jr. sold 9,500 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $67.96, for a total value of $645,620.00. Following the completion of the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at $3,189,770.56. The trade was a 16.83% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 66,192 shares of company stock valued at $4,709,454. Corporate insiders own 1.29% of the company’s stock.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.